Search results for: Multi-Indication Therapies
Filter search results
Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?
1 May 2019
Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as a way to better…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
1 October 2015
…medicines are to reflect their value, then multi-indication medicines should have different prices across major indication, reflecting different values. Multi-indication pricing (MIP) involves setting a different price for each major…
OHE Launches Discussion Paper and Consultation Exercise on Indication-based Pricing
10 May 2019
Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as a way to better…
Indication-Based Pricing (IBP) Consultation Report
1 April 2020
…we pay for them. As more and more medicines come to market with multiple indications (or even more importantly the unrealised potentialto treat multiple indications), the way we pay for…
What are the Economic Implications of Moving Away from Paying a Single Price for a Single Drug?
9 July 2018
…move to indication-based pricing would: (i) provide efficient R&D incentives which stimulate the development of new indications and greater access for patients, and (ii) increase price competition at indication-level, which…
A Framework for Value-aligned Pricing of Combination Therapies
25 June 2024
…report draws learnings from the literature on multi-indication pricing, which is analogous to the case of combination therapies. Proposed pricing models in this context include those based on net price…
Exploring the Financial Sustainability of Gene Therapies
5 January 2021
…likely to influence the financial sustainability of this important medical technology. What do gene therapies offer patients and health systems? For patients, there is hope that gene therapies will change…
A global landscape analysis of access to tumour-agnostic therapies
1 December 2025
…approach, requiring additional evidence to support TA-based indications and restricting indications when considerable treatment heterogeneity was observed. HTA Challenges: TA therapies challenge traditional HTA frameworks, which are designed for organ-specific…
Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies
1 June 2021
…These schemes are often less suited to single-administration therapies such as gene therapies. As a result, patients who need early access to these therapies could miss out. What is different…